Anika Therapeutics Inc (ANIK)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $173.07M
Last updated: Nov 17, 2026 at 4:15 PM ET
Anika Therapeutics Inc (ANIK) Stock Chart
Anika Therapeutics (ANIK) has a latest price of $12.85 on Nov 17, 2026, 43.8% below its 52-week high of $22.88. Its price rose 28.6% over the past 12 months. The month-end price fell 52.8% over the 10 years through Oct 2026, a compound annual decline of 7.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $70.39 in Oct 2019 and its lowest $8.26 in Jul 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ANIK with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ANIK.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 39.6%, and over 6 months it fell 13.3%. The month-end price rose 7.4% over the 3 years through Oct 2026, a compound annual rate of 2.4%.
| Period | Change |
|---|---|
| 1 month | -36.4% |
| 3 months | -39.6% |
| 6 months | -13.3% |
| 12 months | +28.6% |
| 12 months, with dividends | +28.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +7.4% | +2.4% |
| 5 years | -49.7% | -12.8% |
| 10 years | -52.8% | -7.2% |
Price by Year
Its best calendar year was 2019, when the price rose 54.3%, and its weakest was 2025, when it fell 41.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $20.95 | +118.0% |
| 2025 | $9.61 | -41.6% |
| 2024 | $16.46 | -27.4% |
| 2023 | $22.66 | -23.4% |
| 2022 | $29.60 | -17.4% |
| 2021 | $35.83 | -20.8% |
| 2020 | $45.26 | -12.7% |
| 2019 | $51.85 | +54.3% |
| 2018 | $33.61 | -37.7% |
| 2017 | $53.91 | +10.1% |
Trading Range
The price is 33.5% below its 50-day average of $19.33 and 21.9% below its 200-day average of $16.45.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $12.85 | |
| 52-week high | $22.88 | -43.8% |
| 52-week low | $9.01 | +42.6% |
| 50-day average | $19.33 | -33.5% |
| 200-day average | $16.45 | -21.9% |
Price Risk
Over 3 years, its largest fall from a peak was 71.8%.
| Measure | Value |
|---|---|
| 1-year beta | 0.71 |
| Largest fall, 1 year | -41.7% |
| Largest fall, 3 years | -71.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ANIK
What is ANIK's 1-year price change?
Anika Therapeutics's price rose 28.6% over the past 12 months. With dividends included, the 12-month total return was 28.6%.
What is ANIK's 5-year price change?
Anika Therapeutics's month-end price fell 49.7% over the 5 years through Oct 2026, a compound annual decline of 12.8%. These figures leave out dividends.
What is ANIK's 52-week high and low?
Anika Therapeutics's 52-week high is $22.88 and its 52-week low is $9.01. Its latest price of $12.85 on Nov 17, 2026 is 43.8% below the high.
What is ANIK's beta?
Anika Therapeutics's 1-year beta against the S&P 500 is 0.71, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 41.7%.
Is the ANIK chart free?
Yes. Advanced Charting for ANIK is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ANIK pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors